Hematology

Clinical pharmacy services in hematology can have a significant impact, and the Pharmacy Times® Hematology resource center provides clinical news and articles about the topic. Here, visitors will find information about upcoming hematology conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
An ongoing phase 2 study is evaluating SY-1425 plus azacitadine in newly-diagnosed unfit patients with acute myeloid leukemia.
 
[[thumbnail_alt_text]]
Patients with non-Hodgkin lymphoma were more likely to discontinue treatment early when prescribed rituximab by physicians who had less experience with the drug.
 
[[thumbnail_alt_text]]
Bemcentinib is being evaluated as a treatment for elderly patients with acute myeloid leukemia whose disease has relapsed.
 
[[thumbnail_alt_text]]
The high cost of treating blood cancer may contribute to delayed initiation of active treatment in newly-diagnosed Medicare beneficiaries.
 
[[thumbnail_alt_text]]
Ravulizumab-cwvz (Ultomiris, Alexion) is indicated to inhibit complement-mediated thrombotic microangiopathy in adult and pediatric patients with atypical hemolytic uremic syndrome.
 
[[thumbnail_alt_text]]
A phase 3 study assessed the efficacy and safety of plitidepsin (Aplidin) in combination with dexamethasone in patients with relapsed/refractory multiple myeloma.
 
[[thumbnail_alt_text]]
Researchers find 4 genetic variants that are strongly associated with the risk of acute lymphoblastic leukemia in children with Down syndrome.
[[thumbnail_alt_text]]
Study finds health-related quality of life is often not collected for novel cancer drugs when they are submitted for reimbursement.
[[thumbnail_alt_text]]
Two cell mutations have been linked to acute myeloid leukemia, but the reason for their cooperation has been unknown.
[[thumbnail_alt_text]]
Study shows the importance of a cancer-causing oncogene, known as SET/TAF1, in triggering cancer cell proliferation.
[[thumbnail_alt_text]]
Daratumumab was approved based on results from part one of the Phase III CASSIOPEIA study.
[[thumbnail_alt_text]]
Study indicated that patients who received radiation 30 days or fewer before their CAR T-cell infusion did not experience serious cytokine release syndrome or neurotoxicity.